SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of product candidates based on the NexACT® technology, today announced that the Japanese Patent Office has issued the Decision to Grant a Patent for NexMed’s patent application entitled, “Prostaglandin Compositions for the Treatment of Male Erectile Dysfunction.” This patent, when issued, will provide Japanese patent protection to September 2021 and is one in a series of patents and pending applications that NexMed owns on Vitaros® and the underlying NexACT technology.
